Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas
CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.
kAm%96 4@==23@C2E:@? :D 56D:8?65 E@ :56?E:7J 4=:?:42==J 5:776C6?E:2E65 5CF8 42?5:52E6D 7@C AC@>:D:?8 E96C2A6FE:4 E2C86ED] &D:?8 25G2?465 86?6C2E:G6 >@56=D 7C@> E96 62C=:6DE DE286D @7 56D:8?[ E96 E62>D 2:> E@ :>AC@G6 E96 BF2=:EJ @7 42?5:52E6 >@=64F=6D 2?5 @AE:>:K6 E96> E@ 249:6G6 36DE\:?\4=2DD 677:424J 2?5 D276EJ 4C:E6C:2]k^Am
kAm&?56C E96 28C66>6?E[ x?D:=:4@ H:== =625 px\5C:G6? 5:D4@G6CJ E@ :56?E:7J >@=64F=6D >66E:?8 AC6567:?65 D4:6?E:7:4 2?5 62C=J 56G6=@A>6?E 4C:E6C:2[ H9:=6 %2<652 H:== 2AA=J :ED 8=@32= 56G6=@A>6?E 42A23:=:E:6D E@ 25G2?46 D6=64E65 42?5:52E6D E9C@F89 4=:?:42= G2=:52E:@?]k^Am
kAmQx 2> 6I4:E65 E@ A2CE?6C H:E9 @?6 @7 E96 E@A =6256CD :? E96 3:@A92C>246FE:42= :?5FDECJ H:E9 >2DD:G6 4@>A6E6?46 :? 86?6C2E:G6 px[Q D2:5 kDEC@?8mp=6I +92G@C@?<@G[ !9]s][ 7@F?56C[ rt~ 2?5 rq~ @7 x?D:=:4@ |65:4:?6k^DEC@?8m] QpD H6 566A6? E96 :?E68C2E:@? @7 86?6C2E:G6 px :?E@ 6G6CJ DE286 @7 E96 A92C>2 G2=F6 492:?[ x 36=:6G6 E96 7FEFC6 @7 A92C>246FE:42= DFA6C:?E6==:86?46 92D E96 A@E6?E:2= E@ 56=:G6C E96 9:896DE BF2=:EJ 2?5 5:776C6?E:2E65 5CF8D] %9:D :D 2 7F?52>6?E2= DE6A @? @FC ;@FC?6J E@H2C5 6IE6?D:@? @7 962=E9J AC@5F4E:G6 =:76]Qk^Am
kAmQqJ 4@>3:?:?8 %2<652VD 566A 5:D62D6 3:@=@8J 6IA6CE:D6 H:E9 x?D:=:4@VD px\6?23=65 5:D4@G6CJ 42A23:=:E:6D[ E9:D 4@==23@C2E:@? D66<D E@ 56=:G6C >62?:?87F= EC62E>6?E @AE:@?D 7@C A2E:6?ED 3J :56?E:7J:?8 4=:?:42==J 5:776C6?E:2E65 E96C2A:6D[Q D2:5 kDEC@?8mr9C:D pC6?5E[ !9]s][ r9:67 $4:6?E:7:4 ~77:46C 2?5 w625 @7 #6D62C49 2E %2<652k^DEC@?8m] Q%96 A2CE?6CD9:A 2=D@ DFAA@CED %2<652VD EC2?D:E:@? E@ 2? px\?2E:G6 5:D4@G6CJ >@56=[ 2D H6 :?E68C2E6 2FE@>2E:@?[ C@3@E:4D[ 2?5 86?6C2E:G6 px E@ 25G2?46 9:89\BF2=:EJ 42?5:52E6D >@C6 677:4:6?E=J]Qk^Am
kAm&?56C E96 28C66>6?E[ x?D:=:4@ H:== C646:G6 2AAC@I:>2E6=J Se_ >:==:@? :? AC@;64E :?:E:2E:@? 766D[ ?62C\E6C> A2J>6?ED 2?5 >:=6DE@?6D[ 2?5 :D 6=:8:3=6 7@C DF446DD\32D65 AC64=:?:42=[ 4=:?:42=[ 4@>>6C4:2= 2?5 D2=6D >:=6DE@?6 A2J>6?ED E92E 4@F=5 3C:?8 E96 E@E2= 562= G2=F6 E@ 2AAC@I:>2E6=J Se__ >:==:@?[ A=FD E:6C65 C@J2=E:6D @? 7FEFC6 D2=6D]Â k^Am
kAm%96 28C66>6?E 8C2?ED %2<652 6I4=FD:G6 H@C=5H:56 C:89ED E@ 56G6=@A[ >2?F724EFC6[ 2?5 4@>>6C4:2=:K6 ?@G6= E96C2A6FE:4D D6=64E65 E9C@F89 E96 4@==23@C2E:@?]k^Am
kAmkDEC@?8mp3@FE %2<652k^DEC@?8mk^Am
kAm%2<652 :D 7@4FD65 @? 4C62E:?8 36EE6C 962=E9 7@C A6@A=6 2?5 2 3C:89E6C 7FEFC6 7@C E96 H@C=5] (6 2:> E@ 5:D4@G6C 2?5 56=:G6C =:76\EC2?D7@C>:?8 EC62E>6?ED :? @FC 4@C6 E96C2A6FE:4 2?5 3FD:?6DD 2C62D[ :?4=F5:?8 82DEC@:?E6DE:?2= 2?5 :?7=2>>2E:@?[ C2C6 5:D62D6D[ A=2D>2\56C:G65 E96C2A:6D[ @?4@=@8J[ ?6FC@D4:6?46 2?5 G244:?6D] %@86E96C H:E9 @FC A2CE?6CD[ H6 2:> E@ :>AC@G6 E96 A2E:6?E 6IA6C:6?46 2?5 25G2?46 2 ?6H 7C@?E:6C @7 EC62E>6?E @AE:@?D E9C@F89 @FC 5J?2>:4 2?5 5:G6CD6 A:A6=:?6] pD 2 =625:?8 G2=F6D\32D65[ #U2>Ajs\5C:G6? 3:@A92C>246FE:42= 4@>A2?J 9625BF2CE6C65 :? y2A2?[ H6 2C6 8F:565 3J @FC 4@>>:E>6?E E@ A2E:6?ED[ @FC A6@A=6 2?5 E96 A=2?6E] ~FC 6>A=@J66D :? 2AAC@I:>2E6=J g_ 4@F?EC:6D 2?5 C68:@?D 2C6 5C:G6? 3J @FC AFCA@D6 2?5 2C6 8C@F?565 :? E96 G2=F6D E92E 92G6 567:?65 FD 7@C >@C6 E92? EH@ 46?EFC:6D] u@C >@C6 :?7@C>2E:@?[ G:D:E k2 9C67lQ9EEADi^^HHH]E2<652]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]E2<652]4@>k^2m]k^Am
kAmkDEC@?8mp3@FE x?D:=:4@ |65:4:?6k^DEC@?8mk^Am
kAmx?D:=:4@ |65:4:?6 :D 2 A:@?66C:?8 8=@32= 3:@E649?@=@8J 4@>A2?J 565:42E65 E@ :?E68C2E:?8 2CE:7:4:2= :?E6==:86?46 2?5 2FE@>2E:@? E649?@=@8:6D E@ 2446=6C2E6 5CF8 5:D4@G6CJ[ 5C:G6 :??@G2E:@? :? E96 =:76 D4:6?46D[ 2?5 6IE6?5 962=E9 =@?86G:EJ] %96 4@>A2?J H2D =:DE65 @? E96 |2:? q@2C5 @7 E96 w@?8 z@?8 $E@4< tI492?86 @? s646>36C b_[ a_ad[ F?56C E96 DE@4< 4@56 _behe]wz]k^Am
kAmqJ :?E68C2E:?8 px 2?5 2FE@>2E:@? E649?@=@8:6D 2?5 566A :?\9@FD6 5CF8 5:D4@G6CJ 42A23:=:E:6D[ x?D:=:4@ :D 56=:G6C:?8 :??@G2E:G6 5CF8 D@=FE:@?D 7@C F?>6E ?665D :?4=F5:?8 7:3C@D:D[ @?4@=@8J[ :>>F?@=@8J[ A2:?[ 2?5 @36D:EJ 2?5 >6E23@=:4 5:D@C56CD] u@C >@C6 :?7@C>2E:@?[ A=62D6 G:D:E k2 9C67lQ9EEADi^^HHH]:?D:=:4@]4@>^Q E2C86ElQ03=2?<Q C6=lQ?@7@==@HQmHHH]:?D:=:4@]4@>k^2m]k^Am
kA :5lQ!&#{Qmk:>8 E:E=6lQr:D:@?Q H:5E9lQ`aQ 96:89ElQ`aQ 2=ElQr:D:@?Q DC4lQ9EEADi^^6586]AC?6HDH:C6]4@>^4^:>8^72G:4@?]A?8nD?lr}hebabU2>AjD5la_ae\_f\_`Q ^m ':6H @C:8:?2= 4@?E6?Eik2 :5lQ!#}&#{Q C6=lQ?@7@==@HQ 9C67lQ9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^:?D:=:4@\>65:4:?6\2??@F?46D\4@==23@C2E:@?\H:E9\E2<652\E@\25G2?46\DEC2E68:4\2:\5CF8\5:D4@G6CJ\b_ag`eddh]9E>=Q E2C86ElQ03=2?<Qm9EEADi^^HHH]AC?6HDH:C6]4@>^?6HD\C6=62D6D^:?D:=:4@\>65:4:?6\2??@F?46D\4@==23@C2E:@?\H:E9\E2<652\E@\25G2?46\DEC2E68:4\2:\5CF8\5:D4@G6CJ\b_ag`eddh]9E>=k^2mk^Am
kAm$~&#rt x?D:=:4@ |65:4:?6k^Am
kAmk:>8 2=ElQQ DC4lQ9EEADi^^CE]AC?6HDH:C6]4@>^CE]8:7n}6HDxE6>x5lr}hebabU2>Aj%C2?D>:DD:@?0x5la_ae_f_`aa`e!#0}t($0&$!#00000r}hebabU2>Ajs2E6x5la_ae_f_`Q DEJ=6lQ3@C56Ci_AIj H:5E9i`AIj 96:89Ei`AIjQ ^mk^Am
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.